natgillin/translations-raw huggingface dataset:
The safety and efficacy of EMEND 40 mg in children and adolescents below 18 years of age has not yet been established. 
Sigurnost i djelotvornost lijeka EMEND 40 mg u djece i adolescenata mlađih od 18 godina nisu još ustanovljene.
The effects of EMEND or other medicines might be influenced if you take EMEND together with other medicines including those listed below. 
Učinak lijeka EMEND ili drugih lijekova može se promijeniti ako uzimate EMEND zajedno s drugim lijekovima, uključujući sljedeće lijekove.
EMEND 125 mg and 80 mg hard capsules are supplied in the following pack sizes: - Aluminium blister containing one 80 mg capsule - 2-day treatment pack containing two 80 mg capsules - 5 Aluminium blisters each containing one 80 mg capsule - Aluminium blister containing one 125 mg capsule - 5 Aluminium blisters each containing one 125 mg capsule - 3-day treatment pack containing one 125 mg capsule and two 80 mg capsules 
EMEND 125 mg i 80 mg tvrde kapsule dostupne su u sljedećim veličinama pakiranja: - aluminijski blister s jednom kapsulom od 80 mg - pakiranje za dvodnevno liječenje koje sadrži dvije kapsule od 80 mg - 5 aluminijskih blistera sa po jednom kapsulom od 80 mg - aluminijski blister s jednom kapsulom od 125 mg - 5 aluminijskih blistera sa po jednom kapsulom od 125 mg - pakiranje za trodnevno liječenje koje sadrži jednu kapsulu od 125 mg i dvije kapsule od 80 mg.
Do not give EMEND 80 mg and 125 mg capsules to children under 12 years of age, because the 80 mg and 125 mg capsules have not been studied in this population. 
Nemojte davati EMEND 80 mg i 125 mg kapsule djeci mlađoj od 12 godina, zato što kapsule od 80 mg i 125 mg nisu ispitane u ovoj populaciji.
The adverse reactions profiles in adults in the Multiple-Cycle extension of HEC and MEC studies for up to 6 additional cycles of chemotherapy were generally similar to those observed in Cycle 1. 
Profili nuspojava u odraslih u višekratnim ciklusima produžetka HEC i MEC ispitivanja s najviše 6 dodatnih ciklusa kemoterapije uglavnom su bili slični onima opaženima u 1. ciklusu.
Due to modest decreases in protein binding of aprepitant in patients with renal disease, the AUC of pharmacologically active unbound aprepitant was not significantly affected in patients with renal impairment compared with healthy subjects. 
Umjereno smanjeno vezanje aprepitanta za proteine u bolesnika s bubrežnom bolešću nije značajno utjecalo na AUC nevezanog, farmakološki aktivnog aprepitanta u bolesnika s oštećenjem funkcije bubrega u odnosu na zdrave ispitanike.
Control regimen n/m (%) 
Kontrolni režim liječenja n/m (%)
Fosaprepitant placebo, aprepitant placebo, and dexamethasone placebo (in the evenings on Days 3 and 4) were used to maintain blinding (see section 4.2). 
Kako bi se održalo zaslijepljenje, korištene su kombinacije fosaprepitant placebo, aprepitant placebo i deksametazon placebo (uvečer 3. i 4. dana) (vidjeti dio 4.2).
Elderly ( 65 years) 
Starije osobe (≥ 65 godina)
Dexamethasone should also be administered in the evenings on Days 3 and 4. 
Deksametazon također treba primijeniti uvečer 3. i 4. dan liječenja.
You may need to use a different or an extra non-hormonal contraceptive during treatment with this medicine and for up to 2 months after treatment has finished. 
Treba koristiti zamjenske ili dodatne nehormonske metode kontracepcije za vrijeme i do 2 mjeseca nakon završetka liječenja.
No dose adjustment is necessary for patients with renal impairment or for patients with end stage renal disease undergoing haemodialysis (see section 5.2). 
Nije potrebno prilagođavati dozu u bolesnika s oštećenjem funkcije bubrega ili u bolesnika sa završnim stadijem bolesti bubrega koji su na hemodijalizi (vidjeti dio 5.2).
even if their signs of illness are the same as yours. 
čak i ako su njihovi znakovi bolesti jednaki.
Psychiatric disorders anxiety uncommon disorientation, euphoric mood rare 
Psihijatrijski poremećaji anksioznost manje često dezorijentacija, euforično raspoloženje rijetko
Dexamethasone: A single 40 mg dose of aprepitant, when co-administered with a single oral dose of dexamethasone 20 mg, increased the AUC of dexamethasone by 1.45-fold. 
Deksametazon: Istodobna primjena jednokratne doze od 40 mg aprepitanta s peroralnim deksametazonom u jednokratnoj dozi od 20 mg povećala je AUC deksametazona za 1,45 puta.
Aprepitant should be used with caution in these patients (see sections 4.4 and 5.2). 
U tih bolesnika aprepitant treba primjenjivati uz oprez (vidjeti dijelove 4.4 i 5.2).
Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK1) receptors. 
Aprepitant je selektivan antagonist visokog afiniteta za ljudski receptor neurokinina 1 (NK1) supstancije P.
BLISTER TEXT 
TEKST NA BLISTERU
Complete response (no emesis and no rescue therapy) Overall (0-120 hours) 
Potpuni odgovor (izostanak povraćanja i bez dodatnih lijekova) Ukupno (0-120 sati)
Make sure the oral dispenser contains the prescribed dose. 
Provjerite sadrži li oralni dozator propisanu dozu.
Following a single oral dose of aprepitant 165 mg to healthy volunteers, the mean AUC0-∞ of aprepitant was 32.5 µg•hr/mL and the mean maximal aprepitant concentration was 1.67 µg/mL. 
Nakon primjene jednokratne peroralne doze aprepitanta u dozi od 165 mg u zdravih dobrovoljaca, AUC0-∞ aprepitanta iznosio je 32,5 µg•hr/ml, a srednja vršna koncentracija aprepitanta iznosila je 1,67 µg/ml.
Interaction studies with aprepitant 165 mg and chemotherapeutic medicinal products have not been conducted; however, based on studies with 3-day regimen of oral aprepitant and docetaxel and vinorelbine, EMEND 165 mg is not expected to have a clinically relevant interaction with intravenously administered docetaxel and vinorelbine. 
Ispitivanja interakcije aprepitanta 165 mg i i kemoterapeutika nisu provedena, međutim na temelju ispitivanja trodnevnog režima liječenja peroralno primjenjenim aprepitantom i docetakselom i vinorelbinom, ne očekuju se klinički značajne interakcije lijeka EMEND 165 mg s intravenski primjenjenim docetakselom i vinorelbinom.
Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4. 
Deksametazon treba primijeniti 1. dan liječenja 30 minuta prije kemoterapije i 2. do 4. dana ujutro.
EMEND capsules can be taken with or without food. 
EMEND kapsule se mogu uzimati s hranom ili bez nje.
If the dose is not administered immediately after measuring, store filled oral dispenser(s) in the refrigerator between 2°C-8°C for up to 72 hours prior to use. 
Ukoliko doza neće biti primijenjena odmah nakon mjerenja, čuvajte napunjeni(e) oralni(e) dozator(e) u hladnjaku između 2°C i 8°C do 72 sata prije primjene.
PRIMARY ENDPOINT Complete response 
PRIMARNI ISHOD Potpuni odgovor
The total exposure of orally administered CYP3A4 substrates may increase up to approximately 3-fold for 2 days following a single 165 mg dose of EMEND and decreasing to baseline approximately 4 days after dosing of 165 mg EMEND. 
Ukupna izloženost supstrata CYP3A4 koji se primjenjuju peroralno može narasti do približno 3 puta 2 dana nakon jednokratne doze lijeka EMEND 165 mg i sniziti se na početne vrijednosti približno 4 dana nakon primjene lijeka EMEND 165 mg.
Do not give EMEND 165 mg to children and adolescents under 18 years of age, because the 165 mg capsules have not been studied in this population. 
Nemojte davati EMEND 165 mg djeci i adolescentima mlađim od 18 godina, zato što kapsule od 165 mg nisu ispitane u ovoj populaciji.
Day 1: - Give this medicine one hour before the start of the chemotherapy session. 
1. dan: - Lijek dajte jedan sat prije početka kemoterapije.
Table 1 Percent of post-operative adults responding by treatment group Combined results from 2 Phase III trials 
Tablica 1 Postotak postoperativnih odraslih koji su reagirali na liječenje, kombinirani rezultati iz 2 ispitivanja faze III
Concomitant administration of EMEND with herbal preparations containing St. John's Wort (Hypericum perforatum) is not recommended. 
Ne preporučuje se istodobna primjena lijeka EMEND i biljnih lijekova koji sadrže gospinu travu (Hypericum perforatum).
There are some medicines that should not be taken with EMEND (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment (see also ‘Do not take EMEND'). 
Neki se lijekovi ne smiju uzimati s lijekom EMEND (npr. pimozid, terfenadin, astemizol i cisaprid), ili je potrebno prilagoditi njihovu dozu (vidjeti i dio "Nemojte uzimati EMEND").
OTHER PRESPECIFIED ENDPOINTS Complete response 
DRUGI PRETHODNO ODREĐENI ISHODI Potpuni odgovor
If you or the child are pregnant or breast-feeding, may be pregnant or are planning to have a baby, ask the doctor for advice before taking this medicine. 
Ako ste Vi ili dijete trudni ili dojite, ako biste mogli biti trudni ili planirate imati dijete, obratite se liječniku za savjet prije nego uzmete ovaj lijek.
165 mg orally none none none 
EMEND 165 mg peroralno ništa ništa ništa
The 3-day oral aprepitant regimen resulted in an about 30-35 % reduction in AUC of CYP2C9 substrates and up to a 64 % decrease in ethinyl estradiol trough concentrations. 
Trodnevni režim liječenja peroralnim aprepitantom smanjio je AUC CYP2C9 supstrata za oko 30-35%, te snizio najnižu koncentraciju etinilestradiola do 64%.
EMEND 165 mg hard capsules are supplied in cartons in the following pack sizes: - Aluminium blister containing one 165 mg capsule - 6 Aluminium blisters each containing one 165 mg capsule 
EMEND 165 mg tvrde kapsule dostupne su u kutijama u sljedećim veličinama pakiranja: - Aluminijski blister s jednom kapsulom od 165 mg - 6 aluminijskih blistera, svaki s jednom kapsulom od 165 mg
EMEND should not be used during pregnancy unless clearly necessary. 
EMEND se ne smije uzimati u trudnoći, osim ako to nije nužno.
How to take EMEND 
Kako uzimati EMEND
Contains sucrose and lactose. 
Sadrži saharozu i laktozu.
For CYP2C9 and CYP3A4 substrates the induction is transient with a maximum effect reached after 3-5 days. 
Za supstrate CYP2C9 i CYP3A4 indukcija je prolazna, s najsnažnijim učinkom postignutim nakon 3-5 dana.
EMEND 40 mg is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. 
EMEND 40 mg je indiciran za prevenciju postoperativne mučnine i povraćanja (engl.
The powder for oral suspension contains sucrose and lactose. 
Prašak za oralnu suspenziju sadrži saharozu i laktozu.
* The confidence intervals were calculated with no adjustment for age category (< 55 years, ≥ 55 years) and investigator group, which were included in the primary analysis of odds ratios and logistic models. 
* Intervali pouzdanosti izračunati su bez prilagođavanja prema dobi (<55 godina, ≥55 godina) i ispitivaču, a koji su obuhvaćeni primarnom analizom omjera šansi i logističkih modela.
It is not known whether aprepitant is excreted in human milk; therefore, breast-feeding is not recommended during treatment with EMEND. 
Nije poznato izlučuje li se aprepitant u majčino mlijeko u ljudi, stoga se ne preporučuje dojenje tijekom liječenja lijekom EMEND.
Methylprednisolone: Although the concomitant administration of methylprednisolone with the single 40 mg dose of aprepitant has not been studied, a single 40 mg dose of aprepitant produces a weak inhibition of CYP3A4 and it is not expected to alter the plasma concentrations of methylprednisolone to a clinically significant degree. 
Iako nije ispitivana istodobna primjena metilprednizolona s jednokratnom dozom od 40 mg aprepitanta, jedna doza od 40 mg aprepitanta uzrokuje slabu inhibiciju CYP3A4 i ne očekuje se da bi promijenila koncentracije metilprednizolona u plazmi do klinički značajnog stupnja.
Further studies evaluating the use of aprepitant in paediatric patients are on-going (see section 4.2 for information on paediatric use). 
Daljnja ispitivanja primjene aprepitanta u pedijatrijskih bolesnika su u tijeku (vidjeti dio 4.2 za podatke o pedijatrijskoj primjeni).
Titanium dioxide (E 171) Indigo carmine (E 132) 
Ovojnica kapsule želatina titanijev dioksid (E 171) indigo karmin (E 132)
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these medicinal products with EMEND 165 mg. 
Treba uzeti u obzir mogući učinak povišenih koncentracija midazolama, ili drugih benzodiazepina koji se metaboliziraju putem CYP3A4 (aprazolam, triazolam) u plazmi, prilikom istodobne primjene tih lijekova s lijekom EMEND 165 mg.
Dexamethasone: The usual oral dexamethasone dose should be reduced by approximately 50 % when co-administered with EMEND 125 mg/80 mg regimen. 
Deksametazon: uobičajenu peroralnu dozu deksametazona treba sniziti za približno 50% primjenjuje li se istodobno s režimom liječenja lijekom EMEND 125 mg/80 mg.
Hold the EMEND powder for oral suspension sachet upright and shake the contents to the bottom before opening the sachet. 
Prije nego što otvorite vrećicu lijeka EMEND prašak za oralnu suspenziju, držite je uspravno i protresite kako bi sav sadržaj vrećice pao na dno.
Do not give EMEND 40 mg to children and adolescents under 18 years of age, because the 40 mg capsules have not been studied in this population. 
Nemojte davati EMEND 40 mg djeci i adolescentima mlađim od 18 godina, zato što kapsule od 40 mg nisu ispitane u ovoj populaciji.
PET/aluminium/LLDPE sachets 
PET/aluminij/LLDPE vrećice.
EMEND 80 mg capsule 
EMEND 80 mg kapsula
Fill the 5 mL oral dispenser with 4.6 mL of water from the mixing cup. 
Napunite oralni dozator od 5 ml s 4,6 ml vode iz čaše za miješanje.
Studies evaluating the use of aprepitant in paediatric patients are on-going (see section 4.2 for information on paediatric use). 
Ispitivanja primjene aprepitanta u pedijatrijskih bolesnika su u tijeku (vidjeti dio 4.2 za podatke o primjeni u pedijatrijskih bolesnika).
In a juvenile toxicity study in dogs treated from post natal day 14 to day 42, a decreased testicular weight and Leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and oedema of vaginal tissues were seen in females from 4 mg/kg/day. 
U ispitivanju toksičnosti na štenadi liječenoj od 14. do 42. postnatalnog dana opažena je smanjena težina testisa i veličina Leydigovih stanica u mužjaka kod doze od 6 mg/kg na dan i povećana težina uterusa, hipertrofija uterusa i cerviksa te edem vaginalnog tkiva u ženki kod doza od 4 mg/kg na dan.
The most common adverse reaction reported at a greater incidence in adults treated with 40 mg aprepitant (1.1 %) than with ondansetron (1.0 %) was ALT increased. 
Najčešće prijavljena nuspojava, zabilježena u većoj incidenciji u odraslih koji su primali 40 mg aprepitanta (1,1%) nego u bolesnika koji su primali ondanzetron (1,0%) bio je povišeni ALT.
* - Overall phase 
* - cijelo razdoblje
Always take this medicine or give this medicine to the child exactly as the doctor, pharmacist or nurse has told you. 
Uvijek uzmite ovaj lijek ili dajte ovaj lijek djetetu točno onako kako su Vam rekli liječnik, ljekarnik ili medicinska sestra.
• Use the 5 mL oral dispenser to measure 4.6 mL of water, which is added into the mixing cup. 
• Pomoću oralnog dozatora od 5 ml izmjerite 4,6 ml vode, koja se dodaje u čašu za miješanje.
EMEND 125 mg capsule 
EMEND 125 mg kapsula
The mean peak plasma concentration (Cmax) of aprepitant occurred at approximately 4 hours (Tmax). 
Srednja vršna koncentracija aprepitanta u plazmi (Cmax) postignuta je nakon otprilike 4 sata (tmax).
Occupancy of brain NK1 receptors by aprepitant correlate well with aprepitant plasma concentrations. 
Vezanje aprepitanta za NK1 receptore u mozgu je povezana s koncentracijama aprepitanta u plazmi.
The recommended dose is 125 mg orally once daily one hour before start of chemotherapy on Day 1 and 80 mg orally once daily on Days 2 and 3 in the morning. 
Preporučena doza je 125 mg peroralno jedanput na dan jedan sat prije početka kemoterapije 1. dan liječenja te doza od 80 mg peroralno jedanput dnevno 2. dan i 3. dan ujutro.
Co-administration of EMEND with active substances that are known to be metabolized by CYP2C9 (e.g., phenytoin, warfarin), may result in lower plasma concentrations of these active substances. 
Istodobna primjena lijeka EMEND s djelanim tvarima za koje se zna da se metaboliziraju putem CYP2C9 (npr. fenitoinom i varfarinom) može sniziti koncentraciju tih djelatnih tvari u plazmi.
After reconstitution: 
Nakon pripreme za primjenu:
Given the short duration of increased exposure, dose reduction of the immunosuppressant based on Therapeutic Dose Monitoring is not recommended on the day of and the day after administration of EMEND 165 mg. 
Therepeutic Dose Monitoring) i obzirom na kratko trajanje i povećanje izloženosti, ne preporučuje se smanjivati dozu imunosupresiva na dan i dan nakon primjene lijeka EMEND 165 mg.
Gender: Following oral administration of a single 125 mg dose of aprepitant, the Cmax for aprepitant is 16 % higher in females as compared with males. 
Spol: Nakon jednokratne peroralne primjene doze aprepitanta od 125 mg, Cmax aprepitanta bio je 16% viši u žena nego u muškaraca.
Single-use carton 
Kutija za jednokratnu primjenu
The potential for effects of aprepitant on fertility has not been fully characterised because exposure levels above the therapeutic exposure in humans could not be attained in animal studies. 
Mogući učinci aprepitanta na plodnost nisu u potpunosti opisani jer se u ispitivanjima na životinjama nisu mogle postići razine izloženosti iznad terapijske izloženosti u ljudi.
Following oral administration of a single 40 mg dose of EMEND in the fasted state, the AUC0- (mean ± SD) was 8.0 ± 2.1 µg • h/mL and the Cmax was 0.7 ± 0.24 µg/mL. 
Nakon peroralne primjene jedne EMEND 40 mg doze natašte, AUC0-∞ aprepitanta (srednja vrijednost ± SD) iznosio je 8,0 ± 2,1 µg • h/ml, a Cmax je iznosila 0,7 ± 0,24 µg/ml.
In a randomised, parallel, double-blind, active-controlled study, fosaprepitant 150 mg (N=1,147) was compared with a 3-day aprepitant regimen (N=1,175) in adult patients receiving a HEC regimen that included cisplatin (≥ 70 mg/m2). 
U randomiziranom, paralelnom, dvostruko slijepom ispitivanju kontroliranom aktivnim komparatorom, fosaprepitant u dozi od 150 mg (N=1147) uspoređen je s trodnevnim režimom liječenja aprepitantom (N=1175) u odraslih bolesnika koji su primali jako emetogenu kemoterapiju cisplatinom (≥70 mg/m2).
EMEND powder for oral suspension contains sucrose and lactose. 
EMEND prašak za oralnu suspenziju sadrži saharozu i laktozu.
Aprepitant regimen (N= 433) 
Režim s aprepitantom (N= 433)
EMEND causes a transient mild induction of CYP2C9, CYP3A4 and glucuronidation approximately one week after treatment. 
EMEND uzrokuje prolaznu blagu indukciju CYP2C9, CYP3A4 i glukuronidaciju približno tjedan dana nakon primjene.
Concomitant administration of EMEND with active substances that strongly induce CYP3A4 activity (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination results in reductions of the plasma concentrations of aprepitant that may result in decreased efficacy of EMEND. 
Treba izbjegavati istodobnu primjenu lijeka EMEND i djelatnih tvari koje snažno induciraju aktivnost CYP3A4 (npr. rifampicin, fenitoin, karbamazepin, fenobarbital) jer takva kombinacija dovodi do sniženja koncentracije aprepitanta u plazmi, što može dovesti do smanjenja djelotvornosti lijeka EMEND.
Take the capsule 1 hour before you start your chemotherapy session. 
Uzmite kapsulu 1 sat prije kemoterapije.
Always take EMEND together with other medicines, to prevent nausea and vomiting. 
Uvijek uzmite EMEND zajedno s drugim lijekovima kako biste spriječili mučninu i povraćanje.
The safety and efficacy of EMEND 165 mg in children and adolescents below 18 years of age has not been established. 
Sigurnost i djelotvornost primjene lijeka EMEND 165 mg u djece i adolescenata mlađih od 18 godina nije još ustanovljena.
- If chemotherapy is given, take EMEND 1 hour before you start your chemotherapy session. 
Ako se daje kemoterapija, uzmite EMEND 1 sat prije početka kemoterapije.
Do not use this medicine after the expiry date which is stated on the carton after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji iza oznake "EXP".
Hepatic impairment: Mild hepatic impairment (Child-Pugh class A) does not affect the pharmacokinetics of aprepitant to a clinically relevant extent. 
Oštećenje funkcije jetre: Utjecaj blagog oštećenja funkcije jetre (Child-Pugh stadij A) na farmakokinetiku aprepitanta nije klinički značajan.
The daily dose of dexamethasone on Days 1 and 2 should be reduced by approximately 50 % when co-administered with EMEND 165 mg on Day 1 to achieve exposures of dexamethasone similar to those obtained when given without EMEND 165 mg. 
Uobičajenu dozu deksametazona 1. i 2. dan liječenja treba sniziti za približno 50% primjenjuje li se istodobno s lijekom EMEND 165 mg kako bi izloženost deksametazona bila približno slična onoj bez primjene lijeka EMEND 165 mg.
Microcrystalline cellulose (E 460) Hydroxypropylcellulose (E 463) Sodium laurilsulfate 
Sadržaj kapsule saharoza celuloza, mikrokristalična (E 460) hidroksipropilceluloza (E 463) natrijev laurilsulfat
The mean peak plasma concentration (Cmax) of aprepitant occurred at approximately 4 hours (tmax). 
Srednja vršna vrijednost koncentracije aprepitanta u plazmi (Cmax) se postiže nakon približno 4 sata (Tmax).
EMEND 40 mg hard capsules are supplied in the following pack sizes: - Aluminium blister containing one 40 mg capsule - 5 Aluminium blisters each containing one 40 mg capsule 
EMEND 40 mg tvrde kapsule dostupne su u sljedećim veličinama pakiranja: - aluminijski blister s jednom kapsulom od 40 mg - 5 aluminijskih blistera sa po jednom kapsulom od 40 mg
EMEND may have minor influence on the ability to ride a bicycle and use machines. 
EMEND malo utječe na sposobnost vožnje bicikla i rada sa strojevima.
Post-marketing events of neurotoxicity, a potential adverse reaction of ifosfamide, have been reported after aprepitant and ifosfamide co-administration. 
Nakon stavljanja u promet zabilježeni su slučajevi neurotoksičnosti, moguće nuspojave ifosfamida, nakon istodobne primjene aprepitanta i ifosfamida.
Additionally, no significant nausea in the overall period (0 to 120 hours post-chemotherapy) was evaluated as an exploratory endpoint, and in the acute and delayed phases as a post-hoc analysis. 
Osim toga, izostanak klinički značajne mučnine tijekom cijelog razdoblja (0 do 120 sati poslije kemoterapije) ocijenjen je kao eksploratorna mjera učinka te u post-hoc analizi akutne i kasnije faze.
Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered during this time period. 
Potreban je oprez kad se tijekom tog perioda primjenjuju varfarin, acenokumarol, tolbutamid, fenitoin ili druge djelatne tvari za koje se zna da se metaboliziraju putem CYP2C9.
Tell the doctor or pharmacist if you or the child are taking, have recently taken, or might take any other medicines. 
Obavijestite liječnika ili ljekarnika ako Vi ili dijete uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
What EMEND contains The active substance is aprepitant. 
Što EMEND sadrži Djelatna tvar je aprepitant.
During treatment with EMEND, CYP3A4 is inhibited. 
Tijekom liječenja lijekom EMEND, CYP3A4 je inhibiran.
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. 
Prevencija mučnine i povraćanja povezanih s jako i umjereno emetogenom kemoterapijom raka u djece, male djece i dojenčadi u dobi od 6 mjeseci do manje od 12 godina.
During days 9 through 21 in this study, there was as much as a 64 % decrease in ethinyl estradiol trough concentrations and as much as a 60 % decrease in norethindrone trough concentrations. 
Od 9. do 21. dana ispitivanja zamijećeno je sniženje najniže koncentracije etinilestradiola od čak 64%, odnosno najniže koncentracije noretindrona od čak 60%.
What you need to know before you take or give EMEND 
Što morate znati prije nego počnete uzimati ili davati EMEND